HC Wainwright Has Bearish Forecast for TRVI FY2026 Earnings

Trevi Therapeutics, Inc. (NASDAQ:TRVI) – Research analysts at HC Wainwright reduced their FY2026 earnings per share estimates for Trevi Therapeutics in a report released on Tuesday, November 10th. HC Wainwright analyst B. Folkes now expects that the company will post earnings of ($0.49) per share for the year, down from their previous forecast of ($0.48). HC Wainwright has a “Buy” rating and a $24.00 price target on the stock. The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.48) per share. HC Wainwright also issued estimates for Trevi Therapeutics’ Q4 2026 earnings at ($0.17) EPS, FY2027 earnings at ($0.65) EPS and FY2028 earnings at ($0.72) EPS.

Trevi Therapeutics (NASDAQ:TRVI) last announced its quarterly earnings data on Monday, November 9th. The company reported ($0.13) EPS for the quarter, hitting analysts’ consensus estimates of ($0.13).

Several other equities research analysts have also issued reports on TRVI. Cantor Fitzgerald boosted their price target on shares of Trevi Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Morgan Stanley reaffirmed an “overweight” rating and set a $23.00 price objective on shares of Trevi Therapeutics in a report on Friday, August 7th. JonesTrading lifted their target price on shares of Trevi Therapeutics from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Friday, August 14th. B. Riley Financial lifted their target price on shares of Trevi Therapeutics from $21.00 to $31.00 and gave the company a “buy” rating in a research report on Monday, July 20th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Trevi Therapeutics in a research note on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $27.08.

Trevi Therapeutics Trading Down 0.7%

Shares of NASDAQ TRVI opened at $14.81 on Thursday. The business has a fifty day simple moving average of $14.17 and a 200 day simple moving average of $14.46. The firm has a market capitalization of $2.11 billion, a price-to-earnings ratio of -37.97 and a beta of 1.15. Trevi Therapeutics has a one year low of $9.82 and a one year high of $20.22.

Insider Activity at Trevi Therapeutics

In related news, Director Michael Heffernan sold 39,473 shares of the business’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $15.09, for a total value of $595,647.57. Following the sale, the director owned 6,351 shares of the company’s stock, valued at $95,836.59. The trade was a 86.14% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 15.39% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. KBC Group NV bought a new stake in shares of Trevi Therapeutics in the 1st quarter worth about $29,000. Sterling Capital Management LLC lifted its holdings in Trevi Therapeutics by 848.7% during the 3rd quarter. Sterling Capital Management LLC now owns 3,567 shares of the company’s stock valued at $51,000 after purchasing an additional 3,191 shares during the last quarter. Avidity Partners Management LP acquired a new position in Trevi Therapeutics in the first quarter valued at about $79,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in Trevi Therapeutics in the third quarter valued at about $104,000. Finally, Amundi acquired a new position in Trevi Therapeutics in the second quarter valued at about $192,000. 95.76% of the stock is owned by institutional investors.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing treatments for chronic cough and chronic itch. Its lead candidate, Haduvio (oral extended-release nalbuphine), is being studied for conditions including idiopathic pulmonary fibrosis, other interstitial lung diseases and chronic pruritus associated with prurigo nodularis. Nalbuphine acts on opioid receptors, and Trevi is evaluating its potential to reduce these symptoms. The company’s development programs are focused on clinical research; Haduvio is not an approved treatment.